Ferrer unloads another business to focus on branded drugs

After selling its generic drug business to India's Hetero, Spain's Ferrer has sold off an ingredients and flavorings operation. (Ferrer)

European pharma firm Grupo Ferrer is parting with three plants, 140 employees and an ingredients business as it narrows its focus on its branded pharmaceutical business. 

Ferrer has sold HealthTech BioActives (HTBA), a business centered on nutraceuticals, to U.S. private investment group The Riverside Company. Terms of the deal were not disclosed, but HTBA, which makes APIs, excipients, flavorings and sweeteners for the pharmaceutical, nutraceutical and cosmetic industries, had sales of €51 million in 2018, Riverside said.  

RELATED: Spanish API maker Interquim hit with FDA warning letter

Webinar

Bioavailability Enhancement – Industry Insights, Key Challenges & Advanced Development Solutions

Join this webcast on Tuesday, June 16 as experts present the exclusive survey findings and introduce innovative scalable drug delivery technologies proven to address the industry’s growing need for improving solubility and enhancing bioavailability.

The deal includes three Spanish manufacturing plants—two in Barcelona and one in Beniel, Murcia—as well as the 140 employees working for the business, Riverside said. 

“We are very pleased to have reached this deal with Riverside,” Mario Rovirosa, CEO of Ferrer Pharmaceutical, said in a statement. “Not only does it reinforce our corporate strategy to focus on the branded pharma market, but it also offers a future of growth for HealthTech BioActives.”

The sale follows Ferrer’s deal earlier this year to unload its generics business, Tarbis Farma, to India’s Hetero for an undisclosed sum. Rovirosa began slimming Ferrer down after being named CEO in 2018.

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.